Bavarian Nordic ASCHIX:BAVAC 84 ROA % is 0.47% as of Mar. 2026, which is 80% below its 10-year median of 2.39. GuruFocus rates CHIX:BAVAC with a GF Score™ of 84/100 and a GF Value™ of kr175.27 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,423 Biotechnology companies, Bavarian Nordic AS ranks better than 90.86% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Bavarian Nordic AS's annualizedNet Income for the quarter that ended in Mar. 2026 was kr68 Mil.
Bavarian Nordic AS's average Total Assets over the quarter that ended in Mar. 2026 was kr14,528 Mil. Therefore, Bavarian Nordic AS's annualized ROA % for the quarter that ended in Mar. 2026 was 0.47%.
The historical rank and industry rank for Bavarian Nordic AS's ROA % or its related term are showing as below:
CHIX:BAVAc'
s ROA % Range Over the Past 10 Years
Min: -11.65 Med: 2.39 Max: 11.03
Current: 8.19
During the past 13 years, Bavarian Nordic AS's highest ROA % was 11.03%. The lowest was -11.65%. And the median was 2.39%.
CHIX:BAVAc's ROA % is ranked better than 90.86% of 1423
companies
in the Biotechnology industry
Industry Median: -32.9
vs CHIX:BAVAc: 8.19
Bavarian Nordic AS (CHIX:BAVAc) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Bavarian Nordic AS ROA % Related Terms
Bavarian Nordic AS ROA % Historical Data
* Premium members only.
The historical data trend for Bavarian Nordic AS's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bavarian Nordic AS's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bavarian Nordic AS ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bavarian Nordic AS's ROA % distribution charts can be found below:
* The bar in red indicates where Bavarian Nordic AS's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Bavarian Nordic AS (CHIX:BAVAC) has a ROA % of 0.47% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Bavarian Nordic AS and its competitors. This is 80% below median its historical median of 2.39. According to the industry distribution chart, Bavarian Nordic AS ranks #130 out of 1423 companies in the Biotechnology industry, placing it in the top 9.1%.
Is Bavarian Nordic AS's ROA % too high?
Bavarian Nordic AS's current ROA % of 0.47% is 80% below median its 10-year median of 2.39. Based on the distribution chart, Bavarian Nordic AS ranks #130 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bavarian Nordic AS has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bavarian Nordic AS's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bavarian Nordic AS ranks #130 out of 1423 companies for ROA %. This places Bavarian Nordic AS in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Bavarian Nordic AS and its competitors. Bavarian Nordic AS's current ROA % is 0.47%, which is 80% below median its own 10-year median of 2.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bavarian Nordic AS stock overvalued right now?
Based on GuruFocus' analysis, Bavarian Nordic AS (CHIX:BAVAC) is currently considered Fairly Valued. The stock's GF Value™ is kr175.27, compared to a current price of kr188.30 — trading 7.4% above its estimated fair value. The current ROA % is 0.47%, which is 80% below median its 10-year median of 2.39. Bavarian Nordic AS's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Bavarian Nordic AS (CHIX:BAVAC), the current ROA % is 0.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bavarian Nordic AS (CHIX:BAVAC) Overvalued in 2026?
Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued.
The current stock price of kr188.30 is trading 7.4% above its estimated GF Value™ of kr175.27.
GuruFocus considers Bavarian Nordic AS to be Fairly Valued.
Key valuation signals for CHIX:BAVAC:
ROA %: 0.47% (80% below median its 10-year median of 2.39)
GF Value™: kr175.27 vs. price of kr188.30 (7.4% above fair value)
No single metric tells the full story. See the CHIX:BAVAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
84GF Score
Get the complete analysis for CHIX:BAVAC
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BAVAC has been successfully added to your 
